Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2021-08919 | Registry Identifier | CTRP (Clinical Trial Reporting Program) | |
| 2021-0410 | Other Identifier | M D Anderson Cancer Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.
PRIMARY OBJECTIVE:
I. To assess safety by assessing short term toxicity associated with the gastric injection of the novel magnetic tracer.
SECONDARY OBJECTIVES:
I. To determine the feasibility of sentinel lymph node (SLN) imaging and mapping using novel magnetic nanoparticles (iron conjugated polymers in saline suspension [FerroTrace]) for gastric cancer, and to determine whether pre-operative injection, intra-operative injection, or both are feasible.
II. To test the validity of this procedure by correlating sentinel lymph nodes (SLN) to predict pathologic Lymph node (LN)-positive status i.e., will a negative SLN accurately predict the negativity of the other LNs? III. To determine the diagnostic value of additional hematoxylin and eosin (H&E) sections and immunohistochemistry to assess sentinel lymph nodes compared to routine assessment with one H&E stain alone.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I (PREOPERATIVE INJECTION): Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive indocyanine green (ICG) peritumorally.
COHORT II (INTRAOPERATIVE INJECTION): Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort I (preoperative injection) | Experimental | Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally. |
|
| Cohort II (intraoperative) | Experimental | Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gastrectomy | Procedure | Undergo surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety of endoscopic peritumoral gastric injection of FerroTrace | The Bayesian method by Thall et al. will be applied for interim toxicity monitoring. Toxicities are defined as any grade III or greater toxicities attributable to FerroTrace injection, which occur within 24 hours of the injection. Will summarize the rate of adverse events (AEs) in all patients and by cohort, along with the exact 95% confidence interval. | Within 24 hours of the FerroTrace injection |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Contraindications to surgery +/- adjuvant therapy
Allergy or intolerance to iron oxide compounds
Allergy or intolerance to iodides
Iron overload disorder
Pregnant or lactating women*
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Naruhiko Ikoma, MD | Contact | 832-729-2675 | nikoma@mdanderson.org |
| Name | Affiliation | Role |
|---|---|---|
| Naruhiko Ikoma | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | United States |
Not provided
| Label | URL |
|---|---|
| M D Anderson Cancer Center | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D005743 | Gastrectomy |
| D007208 | Indocyanine Green |
| ID | Term |
|---|---|
| D013505 | Digestive System Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Indocyanine Green | Drug | Given peritumorally |
|
|
| Iron Conjugated Polymers in Saline Suspension | Other | Given peritumorally |
|
|
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |